Table 2.
Pretransplant characteristics
| All patients n = 313 | 20-yr-survivors n = 157 | 20-yr-non-survivors n = 141 | P | |
| Recipients | ||||
| Age (yr) | 47 (14-66) | 44 (14-66) | 50 (25-65) | 0.001 |
| Age < 18, n (%) | 2 (0.6) | 2 (1.3) | 0 (0) | 0.06 |
| Age > 55, n (%) | 57 (18) | 19 (12) | 36 (26) | 0.03 |
| Gender, n (%) female | 135 (43) | 77 (49) | 51 (36) | 0.03 |
| labMELD-score | 18.6 (± 7.6) | 19.4 (± 8.3) | 18.1 (± 7.0) | 0.156 |
| Urgent LT, n (%) | 23 (7) | 15 (10) | 8 (6) | 0.21 |
| BMI (kg/m2) | 23.0 ± 3.3 | 22.7 ± 3.0 | 23.5 ± 3.7 | 0.037 |
| HBMI, n (%) | 78 (25%) | 30 (19%) | 45 (32%) | 0.011 |
| HLIP, n (%) | 45 (14%) | 20 (15%) | 23 (19%) | 0.376 |
| Donors | ||||
| Donor age (yr) | 30 (9-64) | 28 (14-64) | 33 (9-60) | 0.099 |
| ET-DRI | 1.35 (± 0.2) | 1.32 (± 0.2) | 1.37 (± 0.2) | 0.121 |
| Transplant | ||||
| Cold ischemia time, h | 10.6 (± 4) | 10.6 (± 4) | 10.7 (± 4) | 0.994 |
| Retransplantation, n (%) | 46 (15) | 18 (11) | 25 (18) | 0.120 |
| Liver function | ||||
| tBili | 8.1 ± 11.9 | 9.0 ± 12.6 | 7.7 ± 11.6 | 0.363 |
| AST | 115 ± 460 | 124 ± 486 | 111 ± 454 | 0.820 |
| ALT | 102 ± 233 | 102 ± 177 | 108 ± 286 | 0.849 |
| INR | 1.76 ± 0.8 | 1.82 ± 0.8 | 1.7 ± 0.8 | 0.226 |
| Clinical characteristics | ||||
| Systolic BP (mmHg) | 120 ± 20 | 119 ± 20 | 122 ± 21 | 0.340 |
| Diastolic BP (mmHg) | 71 ± 11 | 71 ± 12 | 72 ± 11 | 0.353 |
| Laboratory parameters | ||||
| Glucose (mg/dL) | 120 ± 58 | 116 ± 46 | 126 ± 70 | 0.174 |
| Cholesterol (mg/dL) | 134 ± 72 | 129 ± 55 | 138 ± 86 | 0.311 |
| Triglycerides (mg/dL) | 95 ± 67 | 91 ± 56 | 100 ± 80 | 0.326 |
| Creatinine (mg/dL) | 1.0 ± 0.8 | 1.06 ± 1.0 | 0.95 ± 0.4 | 0.247 |
| eGFR (mL/min per 1.73 m2) | 98 ± 59 | 106 ± 70 | 88 ± 39 | 0.007 |
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HLIP: Hyperlipidemia; HBMI: Overweight; MELD: Model for end-stage liver disease; ET-DRI: Eurotransplant donor-risk-index; INR: International normalized ratio.